Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
myFORTic Study: Mycophenolate Sodium Dosing in Kidney Transplant
NCT00941824Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by CHU Saint-Etienne. Primary endpoint: Area under the curve (AUC0 - 12 hours) of MPA and its metabolites MPAG and Ac-MPAG at Month 3. Started Feb 2009; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00941824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941824.